{"filing":{"accession_number":"0001193125-26-306222","cik":"0001613780","ticker":"DBVTF","company_name":"DBV Technologies S.A.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"d156695d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/d156695d8k.htm"},"events":[{"id":18488,"run_id":16619,"accession_number":"0001193125-26-306222","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing DBV Technologies' financial results for the second quarter and half-year 2026, including operating income, R\u0026D and SG\u0026A expenses, net loss of $98.0 million for the six-month period, cash position of $174.9 million, and cash runway into Q3 2027. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial statements and operational highlights relevant to investors assessing the company's financial condition and progress toward FDA approval of its VIASKIN® Peanut Patch.","company_name":"DBV Technologies S.A.","ticker":"DBVTF","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17314,"accession_number":"0001193125-26-306222","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing DBV Technologies' financial results for the second quarter and half-year 2026, including operating income, R\u0026D and SG\u0026A expenses, net loss of $98.0 million for the six-month period, cash position of $174.9 million, and cash runway into Q3 2027. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial statements and operational highlights relevant to investors assessing the company's financial condition and progress toward FDA approval of its VIASKIN® Peanut Patch.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T21:03:37.796222+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17314,"accession_number":"0001193125-26-306222","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing DBV Technologies' financial results for the second quarter and half-year 2026, including operating income, R\u0026D and SG\u0026A expenses, net loss of $98.0 million for the six-month period, cash position of $174.9 million, and cash runway into Q3 2027. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial statements and operational highlights relevant to investors assessing the company's financial condition and progress toward FDA approval of its VIASKIN® Peanut Patch.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T21:03:37.796222+00:00","company_name":"DBV Technologies S.A.","ticker":"DBVTF","filing_date":"2026-07-16"}]}